Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Applovin Corporation (APP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Applovin Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Applovin Corporation trades at $516.61 (market cap $177.37B). The key difference: Applovin Corporation is far larger — about 39.5× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.
| ACAD | APP | |
|---|---|---|
Market Cap | $4.49B | $177.37B |
Sector | Health | Technology |
52-Week High | $28.06 | $733.60 |
52-Week Low | $20.06 | $335.10 |
Enterprise Value | $3.69B | $178.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AppLovin (APP) trades at $543.79, up 3.17% with strong technical momentum and bullish analyst sentiment. The stock demonstrates exceptional profitability with 64.29% net income margins and consistent earnings beats. Recent Q1 2026 results showed $3.56 EPS beating expectations, while technical indicators signal bullish momentum with key resistance at $554. The company's AI-powered advertising platform drives robust revenue growth, with 2026 revenue projected at $6.2 billion.
AppLovin presents compelling growth potential with 88% analyst buy ratings and $644.09 consensus price target, offering 18% upside. However, premium valuations (P/E 47.29, P/S 30.03) and competitive pressures in mobile advertising represent key risks. The upcoming Q2 2026 earnings on August 5th will be crucial for validating the AI growth narrative and sustaining current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →
